Lung Cancer
Latest News
Advertisement
Latest Videos
CME Content
Advertisement
More News
Role of Neoadjuvant I/O in ES NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Patient Selection: Adjuvant Therapy and Testing for ES NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Phase 3 ADAURA Study: EGFR-Mutated NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Role of Postoperative Radiotherapy in Early Stage NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Neoadjuvant Chemotherapy in Early-Stage NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Treatment of Early-Stage NSCLC: Current Standard of Care
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
In an interview with OncLive® Michael Shafique, MD, discusses examples of this groundbreaking research of immunotherapy combinations in NSCLC.
Afatinib was found to be effective when used in Asian and non-Asian patients with non–small cell lung cancer with major uncommon and compound EGFR mutations, irrespective of ethnicity.
Igor I. Rybkin, MD, PhD, discusses the data with these frontline and second-line regimens in extensive-stage small cell lung cancer.
In a special episode of OncLive On AirTM Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in TMB-high solid tumors and addressed the controversy surrounding the approval.
Afatinib was found to be effective and well tolerated when used as a second-line treatment in patients with metastatic squamous carcinoma of the lung.
The FDA has granted osimertinib a priority review designation to a supplemental new drug application for the adjuvant treatment of patients with early-stage EGFR-mutated non–small cell lung cancer following complete tumor resection with curative intent.
The PLCOm2012 risk prediction model is a preferable lung cancer screening method for identifying African American ever-smokers over the current United States Preventive Services Task Force lung cancer screening eligibility criteria, which may help to overcome racial disparities.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5